Finance

Lists
Why is ODTX up 7.21%?
Dive Deeper
ODTX:NASDAQ
Odyssey Therapeutics Inc
$20.53
+7.21%
(+1.38) 1D
Nov 10, 1:44:43 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ODTX...
Open
$18.98
High
$20.95
Low
$18.70
Mkt. cap
986.83M
Avg. vol.
296.44K
Volume
199.37K
52-wk high
$29.05
52-wk low
$15.10
EPS
-$4.02
No. of employees
100
Open
$18.98
High
$20.95
Low
$18.70
Mkt. cap
986.83M
Avg. vol.
296.44K
Volume
199.37K
52-wk high
$29.05
52-wk low
$15.10
EPS
-$4.02
No. of employees
100
News stories
From web sources and news partners
About Odyssey Therapeutics Inc
CEO-
Employees100
Founded2021
HeadquartersBoston, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Websiteodysseytx.com
Analyst ratings
Based on 6 analysts giving stock ratings to ODTX in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for ODTX in the last 3 months.
Highest
Current $20.53
$42.00 (+104.58%)
Average
$35.80 (+74.38%)
Lowest
$27.00 (+31.51%)
Analyst
Recommendation
Action
Price target
Projected
Date
Joseph Pantginis
H.C. Wainwright
Buy
Initiated
$40.00
+94.8%
11/06/2026
David Nierengarten
Wedbush
Buy
Maintained
$30.00
+46.1%
11/05/2026
Jeff Jones
Oppenheimer
Buy
Maintained
$40.00
+94.8%
10/21/2026
Alice Nettleton
UBS
Buy
Maintained
$27.00
+31.5%
10/20/2026
Thomas Deal
Raymond James
Buy
Initiated
$42.00
+104.6%
10/08/2026
Unknown Analyst
Raymond James
Buy
Initiated
$42.00
+104.6%
10/08/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
$44.00
+114.3%
09/21/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
08/11/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
$29.00
+41.3%
08/10/2026
Eric Schmidt FCA
Cantor Fitzgerald
Buy
Initiated
-
-
06/02/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
99.00K
-
-
-
Cost of goods sold
26.32M
-
36.23M
42.12M
Cost of revenue
26.32M
-
36.23M
42.12M
Research and development expenses
-
32.32M
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.16M
7.35M
10.51M
11.24M
Operating expense
10.16M
39.67M
10.51M
11.24M
Total operating expenses
36.48M
39.67M
46.74M
53.36M
Operating income
-36.38M
-39.67M
-46.74M
-53.36M
Other non operating income
539.00K
-117.00K
-138.00K
-194.00K
EBT including unusual items
-35.52M
-38.20M
-52.80M
-53.01M
EBT excluding unusual items
-33.65M
-38.09M
-44.06M
-49.70M
Income tax expense
-56.00K
63.00K
-8.00K
49.00K
Effective tax rate
0.16%
-0.16%
0.02%
-0.09%
Other operating expenses
-
-
-
-
Net income
-35.46M
-38.26M
-52.79M
-53.06M
Net profit margin
-35,820.20%
-
-
-
Earnings per share
-
-6.75
-1.27
-1.02
Interest and investment income
2.20M
1.71M
2.83M
3.86M
Interest expense
-1.00K
-10.00K
-20.00K
-12.00K
Net interest expenses
2.20M
1.70M
2.81M
3.85M
Depreciation and amortization charges
-
-
-
-
EBITDA
-35.19M
-38.50M
-45.69M
-52.35M
Gain or loss from assets sale
780.00K
-33.00K
639.00K
-4.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps